C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on June 17, 2022, regarding an event that occurred on June 15, 2022. The filing addresses a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On June 15, 2022, Alain J. Cohen notified the Board of his withdrawal as a director nominee for re-election at the 2022 Annual Meeting of Stockholders. The withdrawal was not due to any disagreements with the Company regarding strategy, operations, policies, or practices. Consequently, Mr. Cohen will cease to serve as a director and as a member of the Organization, Leadership and Compensation Committee on June 22, 2022.
Outlook and Management Commentary
- The Board has determined it will not nominate a replacement director for election at the 2022 Annual Meeting of Stockholders.
- The Board has committed to appointing two gender diverse directors by the date of the Company's next Annual Meeting of Stockholders.
Key Facts for Investor Verification
- Alain J. Cohen is withdrawing from the Board effective June 22, 2022.
- No replacement director will be nominated for the upcoming 2022 Annual Meeting.
- The Board has set a specific goal to appoint two gender diverse directors by the next Annual Meeting.
- The departure is explicitly stated as not being related to any disagreement with the Company.